IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02625168Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC